Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INCA33890

Bispecific antibody · Immune activation, directed at programmed cell death protein 1 (PDCD1) and transforming growth factor beta receptor II (TGFBR2) · developed by Incyte

Phase 3 Most advanced trial
INCY Developer
1 Registered trials

What is INCA33890?

INCA33890 is a bispecific antibody that binds PD-1 and TGF-beta receptor II (TGFbRII). Binding PD-1 blocks its activation by PD-L1 and PD-L2, and binding TGFbRII blocks TGF-beta from engaging it, relieving T-cell and NK cell suppression in the tumor microenvironment. It is being studied in colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
programmed cell death protein 1 (PDCD1), transforming growth factor beta receptor II (TGFBR2)
Mechanism
Immune activation, directed at programmed cell death protein 1 (PDCD1) and transforming growth factor beta receptor II (TGFBR2)
Pathways
PD-1 signaling, TGF-beta signaling
Therapy area
Oncology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07284849 Phase 3 CRC (Colorectal Cancer) Recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CRC (Colorectal Cancer)

Other drugs acting on PDCD1 / TGFBR2

More from Incyte

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind INCA33890

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.